In vitro protection of human lymphocytes from toxic effects of chlorpyrifos by selenium-enriched medicines

Navaei-Nigjeh, Mona and Asadi, Hamidreza and Baeeri, Maryam and Pedram, Sahar and Rezvanfar, Mohammad Amin and Mohammadirad, Azadeh and Abdollahi, Mohammad (2015) In vitro protection of human lymphocytes from toxic effects of chlorpyrifos by selenium-enriched medicines. Iranian Journal of Basic Medical Sciences, 18 (3). pp. 284-292.

IJBMS_Volume 18_Issue 3_Pages 284-292.pdf

Download (1MB) | Preview
Official URL:


Objective(s): Chlorpyrifos (CP) is a broad-spectrum organophosphorus pesticide used extensively in agricultural and domestic pest control, accounting for 50 of the global insecticidal use. In the present study, protective effects of two selenium-enriched strong antioxidative medicines IMOD and Angipars were examined in human lymphocytes treated with CP in vitro. Materials and Methods: Isolated lymphocytes were exposed to 12 µg/ml CP either alone or in combination with effective doses (ED50) of IMOD (0.2 µg/ml) and Angipars (1 µg/ml). After 3 days incubation, the viability and oxidative stress markers including cellular lipid peroxidation (LPO), myeloperoxidase (MPO), total thiol molecules (TTM), and total antioxidant power (TAP) were evaluated. Also, the levels of tumor necrosis factor-α (TNF-α), as inflammatory index along with acetylcholinesterase (AChE) activity and cell apoptosis were assessed by flow cytometry. Results: Results indicated that effective doses of IMOD and Angipars reduced CP-exposed lymphocyte mortality rate along with oxidative stress. Both agents restored CP-induced elevation of TNF-α and protected the lymphocytes from CP-induced apoptosis and necrosis. Conclusion: Overall, results confirm that IMOD and Angipars reduce the toxic effects associated with CP through free radical scavenging and protection from apoptosis and necrosis.

Item Type: Article
Subjects: QV pharmacology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 03 Oct 2017 17:14
Last Modified: 03 Oct 2017 17:14

Actions (login required)

View Item View Item